Company intelligence / Profile preview
Suzhou Xingming Youjian Biotechnology
Suzhou, Jiangsu, Chinahenlius.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Suzhou Xingming Youjian Biotechnology is a Chinese biotech company focused on developing AAV-based gene therapies for ophthalmic diseases. Its lead asset UGX‑301 is in clinical development for macular dystrophy. Other pipeline assets target age-related macular degeneration and glaucoma and are at the preclinical stage. No published clinical results are available as of May 2025.
- Therapeutic areas
- Ophthalmology
- Modalities
- AAV based gene therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Suzhou Xingming Youjian Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Xingming Youjian Biotechnology.